

CardieX

ASX:CDX

Company Overview

Craig Cooper - Chief Executive Officer
Niall Cairns - Executive Chairman

August 2020



OUR MISSION

To reduce the global impact of cardiovascular disease.

CardieX technology in over a billion homes and clinics worldwide.



KEY COMPANY HIGHLIGHTS

Core technology measures risk & vital signs for arterial & vascular disease.

A world-leader in measuring arterial stiffness and central blood pressure.

World Leading “cuffless” medical sensor technology.

Only FDA-cleared non-invasive measurement of arterial health.

On track for the release of multiple new devices (FDA ‘fast track’ clearance to be obtained) in 2021 targeting key new markets.

Significant ecosystem of new partnerships and licensing revenue.

Substantial patent, trademark, and IP portfolio.

WE'RE SOLVING A GLOBAL PROBLEM

Cardiovascular (CV) disease is the

#1 Killer

of humans globally ¹



Incidence rate continues to rise

Current blood pressure (BP) monitoring solutions do not accurately identify or prevent CV risk



100

YEAR OLD TECHNOLOGY

Global regulatory and policy support calls for more accurate diagnosis of heart diseases based on arterial stiffness.

THE LANCET



World Health Organization



Traditional blood pressure monitors do not measure a specific **individual's risk** for hypertension, cardiovascular disease, and other health disorders.

OUR MARKET

We're focused on the largest health technology markets - cardiovascular & arterial disease and wearable remote patient monitoring.

Significant
addressable
market

1.3B

Global Hypertensives ⁶
(USA 46% of adult population).

1M+ USA based physicians and clinicians.

Global Blood Pressure Monitoring

Market Value 2017 → 2025

USD
1.04 B ²
(Fortune Business Insights)

USD
2.5 B ²
(Fortune Business Insights)

Medical Wearables Market

Market Value 2017 → 2025

USD
12.79 B ³
(Industry Stats Report)

USD
37.67 B ³
(Industry Stats Report)

Digital Health



Market Value 2019 → 2025

USD
103 B ⁴
(Valuates Reports)

USD
509 B ⁵
(Grand View Research)



Current products cover only a small percentage of our total addressable market - specialist clinicians (cardiologists, nephrologists), researchers, and clinical trial services.



Future product portfolio expands our technology into the consumer/home, digital, wearable, hospital, and general clinician markets through a mix of company owned products/licensing/OEM partnerships - all "Powered by ATCOR".




POWERED BY
ATCOR

RELEVANCE DURING PANDEMICS

Leading Comorbidities among COVID-19 Deaths in New York ⁷



- Our SphygmoCor® technology is a market leader in the non-invasive determination of arterial inflammation – the #1 co-morbidity in patients with COVID-19.
- Our new product development is focused on home and wearable solutions for identifying arterial inflammation and overall risk for other arterial health disorders.



Exclusively selected by the Artery Society to measure CBP and arterial stiffness in the CARTESIAN Study - largest study to date on COVID and hypertension.

OUR CURRENT SOLUTIONS

CardieX's ATCOR division develops and licenses products that precisely measure individual risk for hypertension & vascular disease.

- Patented technology measures "central blood pressure" at the aorta/heart rather than "peripheral blood pressure" at the arm as well as arterial stiffness.
- Measuring "central pressure" provides medical and consumer health parameters not otherwise attainable using traditional blood pressure devices.
- Allows more precise and accurate determination of hypertension and risk of vascular related disease such as Alzheimer's, stroke, and other inflammatory disorders.
- Two current products: XCEL and Oscar 2 ABPM
- **The only technology FDA approved to measure central pressure non-invasively in adults that qualifies for Medicare reimbursement.**
- Currently undertaking significant product and market expansion combined with new sales, pricing, and marketing strategies.

Over
1000
peer-reviewed
studies

Over
4400
installations
worldwide






All **"Top 20 Hospitals"** use SphygmoCor technology to measure central blood pressure (cBP)



1,400+ papers have been published in leading peer-reviewed journals like *Hypertension*, *Journal of Clinical Hypertension*, and the *Journal of the American College of Cardiology*



8 out of Top 10 Pharma companies have used SphygmoCor technology in their clinical trials



Over **11,000 patients** have been tested with SphygmoCor technology in pharmaceutical trials





Approved



USA CPT
Reimbursement Code

14

Patents covering significant applications in cardiovascular health and consumer wearables.

16

New Trademarks

CENTRAL BLOOD PRESSURE

CardieX's Complete Vital Signs Solution

Central Blood (cBP) + arterial stiffness provides **complete BP measurements**.

Gold-standard non-invasive cBP in addition to standard BP numbers.

Numerous **medical grade measurements** for heart & arterial health.

Hypertension

Stroke

Liver Disease

Vascular Aging

Inflammation

Alzheimer's

Dementia

Renal Disease

Erectile & Sexual Health



You can't practice medicine anymore without central blood pressure.

Dr. Mark Houston, Director - Hypertension Institute

OUR PARTNERS & CUSTOMERS

We Currently Sell/Lease XCEL SphygmoCor® and Related Products to:

Research and Pharmaceutical companies for clinical trial services related to CVD and hypertension.



Specialist practices-principally Cardiologists, Nephrologists and Endocrinologists for measurement of pulse wave and cBP (central blood pressure).



IDN/health care service providers in the USA for sale to their affiliate hospital and caregiver networks.



Licensing agreement with SunTech Medical for 24-hour Ambulatory Blood Pressure Measurement (ABPM) for Oscar 2 SphygmoCor® device.



6

Continents

34

Countries

4000+

Installations

THE FUTURE

An ecosystem of connected devices & apps designed to improve daily wellbeing and long-term health.

NEW PRODUCT DEVELOPMENT OVERVIEW

- Multiple new products and revenue streams on track for 2020/2021.
- A complete device & software solutions infrastructure.
- Comprehensive vital signs monitoring solutions.



	Now	2021
Devices	2	5
Partnerships	1	3
Digital	0	3

Current Medical

- XCEL
- Oscar II



POWERED BY
ATCOR 

New Medical/Home-Use (2020/2021)

- v1 CBP monitor
- v2 CBP monitor (arm-based)
- Finger CBP monitor
- OEM partnership (licensing)



Market Opportunity

\$USD 2.5B²

Source: Fortune Business Insights

New Consumer Wearables (2020/2021)

- Mobvoi partnership
- OEM partnerships (licensing)
- Blumio



Market Opportunity

\$USD 37B³

Source: Industry Stats Report

New Arty™ Digital Hub-IoMT (2021)

- Secure cloud
- Clinician portal
- Consumer app



Market Opportunity



\$USD 509B⁵

Source: Grand View Research

HOME/CONSUMER VITAL SIGNS

Reimagining consumer vital signs monitoring.

- Customizable modules and over-the-air feature upgrades.
- Full suite of arterial and consumer health features - "beyond blood pressure".
- Over 15 programmable health data features at launch (Arty™).
- Full clinical remote patient monitoring solution.
- Connected arterial health monitoring for population health management.



WEARABLE SENSOR & TECHNOLOGY LICENSING

A complete wearable health monitoring solution.

Licensed and Company Owned Wearables Based on our Arty™ Platform.

Breakthrough technology for monitoring heart and arterial health with wearable devices.

No commercially available wearable can produce all our heart & arterial health features.











Built on the foundation of our **patented** SphygmoCor® technology.


Significant applications across medical and consumer patient populations and general health monitoring.

First phase studies successfully completed. Currently being implemented into partner (Mobvoi) & new CardieX devices.




Arty™

-  Blood Pressure
-  Central Blood Pressure
-  Arterial Stiffness (ASF™)
-  Heart Stress Score
-  Exercise Capacity (eCap™)
-  Heart Rate Plus (HR+™)
-  Blood Pressure Variability (BPV™)
-  Cardiac Efficiency (HPX™)
-  Heart Rate Variability (HRV+™)
-  Central Pulse Pressure



Arty™ Score

WEARABLE SENSOR & TECHNOLOGY LICENSING CONT.



- Unique heart & arterial indicators
- Calculated from heart pressure pulse from a finger-based PPG sensor



U.S. Patent Pending 63/031645

IoMT - "INTERNET OF MEDICAL THINGS"

An ecosystem of connected medical devices and solutions remotely connecting patients, consumers, and physicians all powered by our SphygmoCor® technology & Arty™ cloud infrastructure.



CARDIEX GOALS IN 2020 & 2021

Significant expansion of new product lines.



Launch of 8 new devices and associated software/digital solutions.



Multiple growth and revenue inflection points throughout the year.



Targeting 3 new FDA-clearances in 2021 in consumer, medical, and wearables.



Multiple new partnerships and licensing of our cBP and wearable sensor technology.



Launch of Mobvoi smartwatch. Commercialization of Blumio sensor partnership.



First to market with consumer cBP and hospital/clinician cBP vital signs device.



Launch of Arty™ app, cloud, SaaS, and clinician software infrastructure.

CardieX




Bringing to market our new proprietary and patented sensor technology for wearables.
World-leading new health data features derived from our SphygmoCor® technology.

FINANCIALS

SALES GROWTH DRIVEN BY


Product and Tech Transformation

Existing Business Revenue



(FY 2020 Unaudited Revenue)

FY24 Revenue Streams



(Target Revenue Mix)

PRODUCT REVENUE METRICS (est)

	SALES TARGET	SUCCESS DRIVER	\$ PER SALES EVENT	GROSS MARGIN	TOTAL ADDRESSABLE MARKET
Professional (XCEL)	Research, Pharma, Specialist Clinicians	Growing clinical recognition of cBP.	\$7,500	>80%	\$USD5B
Digital (App + SaaS)	Physician (ArtyNet portal)	CPT reimbursement.	\$200 p/month.	N/A	~\$7.5B for US in 2020, \$17B in US by 2026
	Consumer (Arty Go app)	Bundled sale with new devices.	\$9.99 p/month	N/A	~\$15B WW in 2020, \$111B WW by 2025
Home & Clinician	Physician	CPT reimbursement and advanced diagnostics.	\$1,000	>70%	1M USA based MD's and clinicians.
	Consumer (Pulse BPM)	Direct marketing & physician referrals.	\$99	>60%	\$USD3B (2025)
	Licensing	Direct sales and marketing to OEM's + device makers.	Licensing revenue, chip sales + revenue share.	>80%	\$USD3B (2025)
Wearables	Patient (prescribed by Physician)	Remote patient monitoring reimbursement (ABPM).	Chip sales + revenue share.	>80%	\$USD3B
	Licensing	World-first medical and consumer health data features.	Royalty fee based on per unit sale	>80%	\$USD37B (2025)

APPENDICES

Board of Directors

Key Management

Locations & Teams

Corporate History

CardieX Cloud Infrastructure

References

BOARD OF DIRECTORS



Executive Director & CEO
Craig R. Cooper

BEC, LLB (Hons)

Co-Founder - NRG Asia-Pacific
Senior Associate Lawyer - Blake Dawson Waldron - counsel to United Airlines, The Disney Corporation, DHL International
Co-Founder - Boost Mobile USA
TV Host & Investor - CNBC's "Adventure Capitalists"
Head of Venture Capital and Digital Media - Saban Capital (USD\$700M)
Founding Partner - Softbank Capital (USD\$500M)
Venture Partner - VantagePoint Capital Partners (USD\$3B)



Non-Executive Director
R. King Nelson

BA, MBA

Director - Regenesys Biomedical
President, CEO & Director - Uptake Medical
Director - Digirad (NASDAQ:DRAD)
President, CEO & Director - Kerberos Proximal Solutions
President, CEO & Director - VenPro Medical (Medtronic)
Division President - Baxter Healthcare (various businesses)
Sales & Marketing - American Hospital Supply



Executive Chairman
Niall Cairns

BEC, ACA, FAICD

Managing Partner - Kestrel Capital Pty Limited
Chairman - Tambla Limited (ASX:TBL)
Director - Chant West Holdings Limited (ASX:CWL)
Director - Carbine Agri-Investment Limited
(formerly Tru-Test Corporation Limited)
Managing Partner - Kestrel Growth Funds
Managing Partner - Carnethy Evergreen Fund



Executive Director, Chief Financial Officer
Jarrod White

BCom., CTA

Traverse Accountants
University of Sydney

KEY MANAGEMENT



Chris Dax

President of ATCOR

Masimo
ISTA Pharmaceuticals
Elan Pharmaceuticals
Valeant



Doug Kurschinski

EVP & Head of Global Sales

Cardiac Pathways (Boston Scientific)
St Jude Medical (Abbott)
Stereotaxis



Rhonda Welch

VP of Health Economics

J&J - Biosense Webster
Baxter Healthcare



ZiHan Lin

VP of Corporate Development

Masimo
Uptake Medical
Harvard / Stanford



Lawrence Chan

Director of Product Development

Cochlear
Silverbrook Research



Dan Posnack

Director of Product Development – Digital Health

ROM Technologies
Modernizing Medicine
DNA Interactive



Ahmad Qasem

Director of Research & Applications

PhD in Biomedical Engineering
Macquarie University



Antony Sloan

Global Head of Marketing & Communications

Masimo
Steris
Avery Dennison



Sameer Molvi

Sr. Engineering Program Mgr.

Commissioning Agents
Breathe Technologies
UC Irvine

LOCATIONS & TEAMS



SILICON VALLEY
Partnership with Blumio

blumio

LOS ANGELES
inHealth Corporate

inHealth
medical services


CHICAGO
ATCOR Sales Management

ATCOR logo


ORANGE COUNTY
CardieX Executive & Corporate

CardieX

CORPORATE HISTORY



CARDIEX CLOUD INFRASTRUCTURE



REFERENCES

1. **World Health Organization.** https://www.who.int/health-topics/cardiovascular-diseases/#tab=tab_1
2. **Fortune Business Insights.** <https://www.fortunebusinessinsights.com/industry-reports/blood-pressure-monitors-market-100059>
3. **Industry Status Report.** <https://industrystatsreport.com/Lifesciences-and-Healthcare/Medical-Wearables-Market-Size-and-Growth/Summary>
4. **Valuates Reports.** <https://reports.valuates.com/market-reports/QYRE-Othe-0A163/digital-health-market>
5. **Grand View Research.** <https://www.grandviewresearch.com/press-release/global-digital-health-market>
6. **Journal of American Society of Hypertension.** <https://www.sciencedirect.com/science/article/abs/pii/S1933171116304892?via%3Dihub>
7. **The Hospitalist.** <https://www.the-hospitalist.org/hospitalist/article/220457/coronavirus-updates/comorbidities-rule-new-yorks-covid-19-deaths>

CONTACT

Craig Cooper
CEO

ccooper@cardiex.com

Niall Cairns
Executive Chairman
nccairns@cardiex.com

